Patient Care Online: Alphyn Biologics Initiates Phase 2b Trial of Botanical Drug for Atopic Dermatitis by Grace Halsey NEWS PROVIDED BY Alphyn Biologics April 8, 2025 Alphyn Biologics has begun patient dosing in its global CLEAR-AD1 phase 2b clinical trial evaluating zabalafin hydrogel for treatment of atopic dermatitis (AD). The randomized, double-blind, vehicle-controlled study is…
Alphyn Announces First Patient Dosed in CLEAR-AD1 Global Phase 2b Clinical Trial Program of Zabalafin Hydrogel for Atopic Dermatitis NEWS PROVIDED BY Alphyn Biologics Apr 08, 2025, 07:30 ET First topical therapeutic to directly treat the immuno-inflammatory and bacterial causes of the disease at all stages, from AD onset through infection ANNAPOLIS, Md., April 8,…
Dermatology Times: Q1 Dermatology Drug & Device Report: FDA Approvals & Pipeline Updates by Emma Andrus NEWS PROVIDED BY Alphyn Biologics March 31, 2025 Exclusive Q1 Report: A comprehensive look at the latest FDA approvals and pipeline developments in dermatology from the first quarter of 2025. Read the Dermatology Times article here. CONTACTS Corporate: Neal…
Alphyn Poster at American Academy of Dermatology Annual Meeting Highlights Potential of Zabalafin Hydrogel as Singular, Comprehensive Treatment for Atopic Dermatitis NEWS PROVIDED BY Alphyn Biologics Mar 10, 2025, 07:30 ET Phase 2a clinical program demonstrates safety and efficacy for all endpoints in AD with and without secondary infection ANNAPOLIS, Md. and ORLANDO, Fla., March 10, 2025 /PRNewswire/ — Alphyn,…
Healio: FDA clears investigational new drug application for Zabalafin Hydrogel by Gabrielle M. Grasso NEWS PROVIDED BY Alphyn Biologics February 21, 2025 The investigational new drug application for Zabalafin Hydrogel for the treatment of mild to moderate atopic dermatitis has been cleared by the FDA, Alphyn Biologics announced in a press release. Read the Healio article…